Trial reportAmerican journal of respiratory and critical care medicine2021
Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis.
Abstract readClinical Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous forThe European respiratory journal · 2025Trial
- Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous forAnnals of the American Thoracic Society · 2023Trial
- Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous forAmerican journal of respiratory and critical care medicine · 2022Trial
- A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous forAmerican journal of respiratory and critical care medicine · 2022Trial
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Cystic fibrosis care today-a narrative review based on views of experts, patients and the public.Wiener klinische Wochenschrift · 2026Review
- Automated Ultrashort Echo Time (UTE) MRI Low Signal Volume Analysis in Stable Pediatric Cystic Fibrosis and After Elexacaftor/Tezacaftor/Ivacaftor Therapy.Journal of magnetic resonance imaging : JMRI · 2026Article
- MRI scoring of pleural findings in cystic fibrosis does not require intravenous contrast media.European radiology · 2026Article
- Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry.ERJ open research · 2026Article
- Pulmonary MRI in Newborns and Children.Journal of magnetic resonance imaging : JMRI · 2025Review
- Multiple-breath washout is more sensitive than spirometry to detect lung function impairment in children and adults with bronchiectasis.ERJ open research · 2025Article
- MDCT and MRI in Bronchiectasis in Older Children and Young Adults - A Non-Inferiority Trial.Indian journal of pediatrics · 2025Article
- Automated scoring of airway abnormalities and mucus plugging in chest magnetic resonance imaging of cystic fibrosis using artificial intelligence.Computational and structural biotechnology journal · 2025Article
- The established chest MRI score for cystic fibrosis can be applied to contrast agent-free matrix pencil decomposition functional MRI: a multireader analysis.Frontiers in medicine · 2025Article
- The ageing of people living with cystic fibrosis: what to expect now?European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoThe European respiratory journal · 2024Observational
- Cystic fibrosis.Nature reviews. Disease primers · 2024Review
- [Cystic fibrosis in childhood and adulthood].Innere Medizin (Heidelberg, Germany) · 2024Review
- Single-centre prospective evaluation of the first 5 years of cystic fibrosis newborn screening in Germany.ERJ open research · 2024Article
- Paediatric Thoracic Imaging in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulation.Children (Basel, Switzerland) · 2024Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on byReply to Dournes2022
Authors and funding
11 authors at 4 institutions in 2 countries.
Mirjam StahlDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0001-6941-8315
Eva SteinkeDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Simon Y GraeberDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-1666-8924
Cornelia JoachimDivision of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center and.
Christoph SeitzDivision of Neonatology, Department of Pediatrics, and.
Hans-Ulrich KauczorDepartment of Translational Pulmonology.
Monika EichingerDepartment of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany.
Susanne HämmerlingDivision of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center and.
Olaf SommerburgDepartment of Translational Pulmonology.
Mark O WielpützDepartment of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0001-6962-037X
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-4057-2199
Cystic Fibrosis Foundation · USHeidelberg University · DEGerman Cancer Research Center · DEHelios Hospital Bad Saarow · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Magnetic Resonance ImagingNeonatal ScreeningChild, PreschoolCystic FibrosisDisease ProgressionEarly DiagnosisFemaleHumansInfantInfant, NewbornLinear ModelsLongitudinal StudiesMaleProspective Studiescystic fibrosisearly lung diseasemagnetic resonance imagingnewborn screeningnoninvasive monitoring
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.